Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in ANCA Vasculitis
NCT01275287Phase 2Withdrawn
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- May 2011
- Primary completion
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) comparing Eculizumab arm with Standard of care (2 arms). Primary endpoint: Birmingham Vasculitis Activity Score at 12 weeks. Planned start May 2011; status: withdrawn.
02
Drugs
eculizumab
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT01275287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01275287.